Semaglutide

Semaglutide is a 31-amino-acid peptide analog of human GLP-1(7-37) with a molecular weight of approximately 4113.6 g/mol. Key structural modifications include an Aib substitution at position 8 (DPP-IV resistance), a C18 fatty diacid chain via a linker at Lys26 (albumin binding), and an Arg34 substitution. These modifications collectively produce a compound with extended pharmacokinetic stability in in-vitro and preclinical models.

Research applications include GLP-1 receptor pharmacology, incretin biology, glucose homeostasis studies, insulin secretion pathway research, appetite signaling investigation, and comparative agonist pharmacology (Semaglutide vs Tirzepatide vs Liraglutide). Its single-receptor GLP-1 profile makes it a key comparator against dual and triple agonists in metabolic research.

Every batch of Semaglutide is synthesized using Solid-Phase Peptide Synthesis (SPPS) and purified via preparative HPLC to eliminate truncated sequences and synthesis byproducts. Final identity confirmation is performed via Electrospray Ionization Mass Spectrometry (ESI-MS), verifying exact molecular weight. Each lot ships with a Certificate of Analysis documenting purity exceeding 99%, giving researchers traceable, batch-specific verification before use in any laboratory protocol.

This product is strictly for research and laboratory use only. It is not approved by the FDA or any global regulatory body for human consumption, veterinary use, or therapeutic application. The purchaser assumes all responsibility for the proper handling, storage, and application of this compound. It must only be handled by qualified professionals in a controlled laboratory setting. By purchasing this product, you agree to abide by all local and international laws regarding the use of research chemicals.